文：点苍鹤近日，国控、上海医药、华润医药、九州通等四大商业龙头2025年上半年财报陆续发布，透过公开的业务发展情况，可以对医药流通行业的发展方向做一个小结和判断。从整体来看，2025年上半年对医药流通行业来说普遍承压，整体营业收入看，上药（1.56%↑）、华润（2.5%↑）、九州通（5.1%↑）小幅增长，而国控则出现小幅下降（2.95%↓）。在净利润方面，上药、九州通分别实现51.56%、...
Source Link文：点苍鹤近日，国控、上海医药、华润医药、九州通等四大商业龙头2025年上半年财报陆续发布，透过公开的业务发展情况，可以对医药流通行业的发展方向做一个小结和判断。从整体来看，2025年上半年对医药流通行业来说普遍承压，整体营业收入看，上药（1.56%↑）、华润（2.5%↑）、九州通（5.1%↑）小幅增长，而国控则出现小幅下降（2.95%↓）。在净利润方面，上药、九州通分别实现51.56%、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.